Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.
企業コードHBIO
会社名Harvard Bioscience Inc
上場日Oct 21, 2013
最高経営責任者「CEO」Duke (John D)
従業員数330
証券種類Ordinary Share
決算期末Oct 21
本社所在地84 October Hill Rd
都市HOLLISTON
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号01746-1371
電話番号15088938999
ウェブサイトhttps://www.harvardbioscience.com/
企業コードHBIO
上場日Oct 21, 2013
最高経営責任者「CEO」Duke (John D)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし